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Abstract
Background Disorders of gastrointestinal (GI) transit
and motility are common, and cause either delayed or
accelerated transit through the stomach, small intes-
tine or colon, and affect one or more regions. Assess-
ment of regional and/or whole gut transit times can
provide direct measurements and diagnostic informa-
tion to explain the cause of symptoms, and plan
therapy. Purpose Recently, several newer diagnostic
tools have become available. The American and Euro-
pean Neurogastroenterology and Motility Societies
undertook this review to provide guidelines on the
indications and optimal methods for the use of transit
measurements in clinical practice. This was based on
evidence of validation including performance charac-
teristics, clinical significance, and strengths of various
techniques. The tests include measurements of: gastric
emptying with scintigraphy, wireless motility capsule,
and 13C breath tests; small bowel transit with breath
tests, scintigraphy, and wireless motility capsule; and
colonic transit with radioopaque markers, wireless
motility capsule, and scintigraphy. Based on the evi-
dence, consensus recommendations are provided for
each technique and for the evaluations of regional and
whole gut transit. In summary, tests of gastrointestinal
transit are available and useful in the evaluation of
patients with symptoms suggestive of gastrointestinal
dysmotility, since they can provide objective diagnosis
and a rational approach to patient management.
Keywords breath tests, dysmotility, gastrointestinal
transit, radioopaque markers, scintigraphy, wireless
motility capsule.
INTRODUCTION
Gastroparesis, constipation, irritable bowel syndrome,
and functional dyspepsia affect over one-third of the
population, consume significant health care resources,
affect quality of life, and cause distress. They are
associated with alterations in gastrointestinal (GI)
transit of food, chyme, and residue. Assessment of
regional (e.g., gastric, small intestinal, or colonic
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transit) or whole gut transit time can facilitate diag-
nosis and rational management of these disorders.
Advances in techniques together with the availabil-
ity of several new tests for the evaluation of GI transit,
and a lack of information, led The American Neuro-
gastroenterology and Motility Society and the Euro-
pean Society of Neurogastroenterology and Motility to
establish a task force to examine the diagnostic utility
of these techniques and make recommendations for
their use in clinical practice. The task force performed
appropriate literature search using PubMed, Google
scholar and Medline and held numerous discussions
and conference calls to develop this narrative review
and provide consensus guidelines that appraise the
transit tests under three main regions; stomach, small
bowel, and colon. Scintigraphy and wireless motility
capsule assess both regional and whole gut transit and
are discussed in multiple sections.
ASSESSMENT OF GASTRIC EMPTYING
The stomach accommodates and temporarily stores
food, triturates and mixes it with secretions, and
empties food (chyme) in an orderly fashion into the
small intestine. Gastric emptying tests are used to
evaluate patients with upper GI symptoms; they detect
delayed (gastroparesis) or rapid emptying (dumping
syndrome). Several tests are available to assess gastric
emptying and the pros and cons of some common
techniques are discussed in Table 1. For this test and
others discussed in this manuscript, we have used a
semi-quantitative score that was developed by us for
the purposes of this document because there is no
validated scale. This scoring system has not been
validated but we hope will serve as a template for
comparison of the various tests.
Gastric emptying scintigraphy
Introduction A radiolabeled meal is widely used to
measure gastric emptying (GE). Following its inges-
tion, the radioactivity measured from the stomach is
directly proportional to the volume of meal remaining
in the stomach. A consensus report has recommended
a standardized meal and has provided normal values for
conducting GE studies in a uniform manner.1
Indications A GE study is indicated for the evaluation
of symptoms suggestive of gastroparesis such as early
satiety, nausea, vomiting, bloating, postprandial full-
ness, and upper abdominal discomfort. A GE study is
performed after excluding gastric outlet obstruction.
Other indications include severe gastro-esophageal re-
flux disease unresponsive to acid suppressants, poorly
controlled diabetes or to assess a generalized gut
motility disorder.2
Study performance 99mTc-sulfur colloid labeled meal is
commonly used to assess solid phase gastric emptying
with scintigraphy. Liquid GE (usually labeled with
indium) is often used to assess postsurgical conditions,
as there can be discrepancy in liquid and solid gastric
emptying after gastric surgery and/or vagotomy.3,4 The
test involves radiation which is increased with use of
simultaneous evaluation of solid and liquid emptying.
The technical conduct, choice of collimator, win-
dows for detection of the isotopes, quantitation and
corrections of radioactivity for isotope decay and depth,
caloric content of the meal, position (upright) and










Validated +++ +++ +++




Availability +++ ++ +
Ease of test performance/
need for specialized personnel
++ ++ ++
Patient inconvenience ++ ++ ++
Patient tolerance +++ +++ +++
Radiation exposure + )/+ )
Expense ++ ++ +
The scoring for each factor was based on the following descriptors:
Validated (+ = limited evidence relating test results to clinical pre-
sentation, diagnosis, and/or treatment; ++ = moderate evidence;
+++ = significant evidence).
Standardized (+ = several distinct protocols for testing; ++ = a few
protocols; +++ = a single uniform protocol).
Provides accurate and quantitative results (+ = testing provides find-
ings that are predominantly qualitative in nature; ++ = testing provides
some quantitative approximation of transit time; +++ = testing pro-
vides accurate transit time).
Availability (+ = test available at only a small number of centers;
++ = test available at modest number of centers; +++ = test widely
available).
Test performance/need for specialized personnel (+ = testing is easy,
protocols are easy, and minimal specialized training required for test
performance; ++ = testing is moderately complicated with more com-
plex protocols that require modest training; +++ = testing is highly
specialized and requires advanced training).
Patient inconvenience (+ = minimal inconvenience in terms of travel
or time commitment; ++ moderate inconvenience because more than
one visit is required or test consumes several hours; +++ = significant
inconvenience because of multiple test visits or long test times).
Patient tolerance (+ = significant discomfort during test preparation or
testing; ++ = moderate discomfort during test preparation or testing;
+++ = little discomfort during test preparation or testing).
Radiation exposure () = no radiation exposure; + = a single radiograph
or low dose radionuclide; ++ = a few radiographs or moderate radionu-
clide dosing; +++ = several radiographs or high doses of radionuclide).
Expense (+ = inexpensive; ++ = moderately expensive; +++ = very
expensive).
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timing of imaging (1, 2, and 4 h after meal – Fig. 1) are
covered in the AMS-Society of Nuclear Medicine
consensus document.1 Standardization of testing in-
cludes overnight fast, avoidance of medications (e.g.,
prokinetics, opiates) that affect gastric emptying for
48–72 h prior to the test, and checking that fasting
blood glucose is <280 mg dL)1 before starting the test.
Subjects may require supplemental insulin, prior to
and immediately after test completion. Smoking is not
permitted during testing. The phase of menstrual cycle
has a minor effect on GE and is generally disregarded in
clinical practice.5–7 Patients are permitted to sit, stand
or walk between images.
Data analysis and endpoints The percentage retention
at 4 h is more reproducible than data acquired during
the first 2 h;8 the 4-h analysis also detects more
abnormal GE among symptomatic patients.9 Gastric
emptying is considered abnormally delayed if greater
that 60% of the meal is retained at 2 h and/or greater
than 10% at 4 h. Other measures of GE include time to
50% emptying (T1/2) and a lag phase for solids.
10–12
However, receiver operating characteristic curves
(ROC) showed that the percent emptied at 1, 2, and 4 h
provided as much diagnostic information as the com-
bined lag time and slope of the postlag emptying curve
which require imaging every 15 min.13,14
Performance characteristics A comprehensive assess-
ment of the performance characteristics of scinti-
graphic GE and the proportion emptied at 2 and 4 h,
and GET1/2 were evaluated in 37 healthy participants.
8
The inter-subject coefficient of variation (COV) at 1, 2,
and 4 h were 62%, 29%, and 8% respectively and the
A
B
Figure 1 Gastric emptying scintigraphy:
examples of (A) Normal gastric emptying
(GE) showing anterior images at 0, 30, 60,
and 120 min for solids labeled with Tc-99
meal, and (B) Delayed GE with retention of
isotope in stomach at 2 and 4 h in a subject
with gastroparesis.
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intra-subject COV were 20%, 14%, and 4% respec-
tively. The inter- and intra-subject COV for GET1/2
were 30% and 14% respectively. The 12% intra-
subject COV for scintigraphic GET1/2 was confirmed in
two other studies.15,16
Responsiveness to treatment As validation of a
diagnostic test for responsiveness requires effective
therapies, the best assessment of GE responsiveness
was shown with the use of cisapride and erythro-
mycin. Gastric emptying was enhanced with cisa-
pride and this was associated with improvement of
symptoms of gastroparesis and dyspepsia.17,18 Simi-
larly, pharmacologic and clinical efficacy of erythro-
mycin was demonstrated with scintigraphic GE.19 A
second level of pharmacological responsiveness was
demonstrated by the predicted pharmacological
effects of atropine (slowing) or erythromycin (accel-
eration).20,21
Clinical significance Delayed GE often forms the basis
for a diagnosis of gastroparesis and helps to identify
patients whose symptoms are likely to benefit from
treatment.22 The results of a GE study are also used to
grade the severity of gastroparesis and provide guidance
on selection of therapy,22 and objectively measure the
response to therapy.19,23
Strengths and confounding issues Studies demon-
strate that delayed GE is found in 30–70% of patients
with upper GI symptoms.24 A delayed GE test confirms
gastric dysmotility but does not prove that symptoms
are due to gastroparesis. Both rapid and delayed GE can
cause similar symptoms. Among tertiary care patients
with endoscopy-negative upper GI symptoms (diag-
nosed as functional dyspepsia, postfundoplication, or
rumination syndrome), GE was delayed in 14% and
accelerated in 23%; among diabetics with such symp-
toms, GE was delayed in 46% and accelerated in 18%
of patients.25
Criteria for rapid GE are less standardized but <38%
retention at 60 min is suggestive of rapid GE.1 The
clinical role of liquid GE studies merits further study
and is of growing interest. In spite of society guidelines,
many centers continue to perform suboptimal studies
(duration 1–2 h) that undermine the quality and utility
of this test.
Recommendations Gastric emptying scintigraphy
should be performed with a low-fat, egg white meal
with imaging at 0, 1, 2, and 4 h to assess emptying of
solids. The 1-h scan is used to detect rapid GE and the 2
and 4 h are used to detect delayed gastric emptying. It
is widely available, validated and reproducible and in-
volves a small amount of radiation. It is recommended
for the evaluation of subjects with suspected gastro-
paresis and/or dumping syndrome. In clinical practice,
the test is hampered by a lack of uniform methodology
across centers.
Wireless motility capsule
Introduction The wireless motility capsule (WMC) is
a single-use, orally ingested, non-digestible, data-
recording capsule that measures pH, pressure, and
temperature throughout the GI tract. This capsule is
capable of measuring regional and whole gut transit
including gastric emptying time (GET), small bowel
transit time (SBTT), colonic transit time (CTT), and
whole gut transit time (WGTT).
Indications A WMC test is approved by the US Food
and Drug Administration (FDA) and indicated for the
evaluation of suspected delayed gastric emptying
(gastroparesis) in disorders such as idiopathic or
diabetic gastroparesis and functional non-ulcer dys-
pepsia.
Study performance The WMC (SmartPill; SmartPill
Corporation, Buffalo, NY, USA), measures 11.7 mm ·
26.8 mm in size and houses sensors for pH (range =
0.05–9.0), pressure (0–350 mmHg) and temperature
(25–49 C), and requires activation using an activa-
tion fixture. The WMC is ingested immediately fol-
lowing a standardized meal comprising of a nutrient
bar (calories = 255; fat = 2.2%) and 50 mL water.
Subjects are not permitted to eat for the next 6 h
while GE of WMC is assessed. For assessment of
WGTT, the receiver is worn on the waist for 3–
5 days during which time the subject is free to
ambulate and is instructed to push the event button
and to keep a diary of events (e.g., meals, sleep, bo-
wel movements). The data recorder is returned and
the information is downloaded via a docking station
for analysis.
Data analysis and endpoints Gastric emptying time,
SBTT, CTT, and WGTT are defined using specific pH
and temperature profiles.26–28 Gastric emptying time is
defined as the duration of time from capsule ingestion
to an abrupt pH rise (usually >3 pH units, see Fig. 2) as
the capsule passes from the acidic antrum to the more
alkaline duodenum.26 The WMC usually requires a
phase 3 migratory motor complex to pass into the
small bowel.29
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Performance characteristics In 87 healthy and 61
gastroparetic individuals who underwent simultaneous
WMC and scintigraphic measurement of GE, the
authors reported correlation coefficient of 0.73 relative
to the 4-h scintigraphic data and 0.63 relative to the
2-h data.26 The sensitivity and specificity of WMC in
detecting delayed GE based on 4 h scintigraphic data
were 0.87 and 0.92, respectively. Utilizing this analy-
sis, the WMC cut-off point for delayed GET that pro-
vides an optimum balance of sensitivity and specificity
for clinical use was 300 min.26 The estimated inter-
subject COV for GET with WMC in health and gast-
roparesis were 28% and 34% respectively and there
was no difference.26
Responsiveness to treatment Pharmacological respon-
siveness in healthy subjects was shown by the ability
of WMC to detect acceleration of gastric emptying
induced by erythromycin and slowing of gastric
emptying by morphine.30
Clinical significance This is discussed below in the
colonic transit assessment of WMC section.
Strengths and confounding issues The WMC provides
a means of measuring transit free of radiation exposure
in ambulatory setting, and has the advantage of
simultaneously measuring GET, SBTT, CTT and
WGTT and providing a pressure activity profile
















Figure 2 Wireless motility capsule: (A) This
figure displays wireless motility capsule
(WMC) profiles from a healthy subject and
shows normal gastric emptying, normal
small bowel transit and normal colonic
transit time, and (B) delayed gastric empty-
ing and delayed colonic transit and delayed
whole gut transit time in a subject with
symptoms of gastroparesis and constipation.
S. S. C. Rao et al. Neurogastroenterology and Motility
 2010 Blackwell Publishing Ltd12
throughout the gut further defining conditions with
altered GI motility.31,32 The disadvantages include
ingestion of a large capsule, and wearing/returning a
data receiver for up to 5 days if WGTT is being
assessed. There is a risk of capsule retention [20/6000
cases (0.33%) as of January 2010] which required
endoscopic removal in two cases. Its use is contrain-
dicated in patients with pseudo-obstruction, ileus, and
gastric bezoar.
Recommendations The WMC is recommended for an
assessment of gastric emptying and regional and whole
gut transit time in individuals with suspected gastro-
paresis and symptoms of upper GI dysmotility. It is
particularly useful for testing individuals with sus-
pected alterations of GI motility in multiple regions.
Gastric emptying breath test (GEBT)
Introduction A test meal labeled with a stable (non-
radioactive) isotope (13C) can be used to measure gas-
tric emptying. The 13C containing moiety is typically
the medium chain fatty acid, 13C-octanoic acid,16,33 or
the edible blue-green algae, 13C-Spirulina platensis.34
When these substances are baked with egg, the 13C
does not dissociate, and it empties from the stomach at
the same rate as other solids. Subsequently, the 13C
containing substrate is either absorbed directly (octa-
noic acid) or digested and then absorbed (Spirulina
platensis). It then becomes part of the body’s bicar-
bonate pool, and is finally excreted by the lungs as
13CO2. Although there are multiple steps in this
process, the rate limiting step for 13CO2 excretion is
gastric emptying.
Indications The 13C-Spirulina platensis GEBT is
indicated for measuring gastric emptying of solids in
adults. A FDA application has been submitted.
Study performance After an overnight fast, the 13C-
labeled test meal (e.g., 100 mg 13C-Spirulina platensis,
27 g freeze-dried egg mix, six saltine crackers, and
180 mL of water) is consumed. Breath samples are
collected at fixed time points (e.g., 45, 150, 180 min),
and mass spectrometry is used to determine the
13CO2/
12CO2 ratio in the samples. The breath samples
are stable for months.35 Less expensive bench-top
infra-red devices have also been validated.36
Data analysis and endpoints Breath testing is an
indirect measure of GE (Fig. 3).16 Multiple mathe-
matical analysis methods have been proposed for the
interpretation of the breath test metrics,33,34,37,38 but
the linear regression method had the highest con-
cordance correlation coefficient with scintigraphic
T1/2.
39 In a large study of 124 patients, linear
regression was used to compare GE breath test
(time points 45, 150, and 180 min) to scintigraphy,
with accurate detection of accelerated or delayed
emptying.34
Performance characteristics The intra-subject COVs
for scintigraphy and the 13C-Spirulina GEBT were
highly comparable (3–4% different) at all time points
from 45 to 180 min in health. Inter-subject COVs at
each time for the GEBT and scintigraphy were typi-
cally 1–4% lower than intra-subject COVs. Indi-
vidual breath samples at 45, 150, and 180 min
predicted emptying category (delayed, normal or
accelerated): at 80% specificity, 45- and 180-min
samples combined were 93% sensitive for identifying
accelerated GE, and 150- and 180-min samples com-
bined were 89% sensitive for delayed GE.34 Intra- and
inter-subject variations of measurements of GE with
the 13C-octanoic acid GEBT were not significantly
































Figure 3 Gastric emptying breath test: Gas-
tric emptying curves in a healthy subject and
in a gastroparetic subject showing percent
dose 13C excreted (kPCD) at different time
points following ingestion of a standardized
13C-Spirulina platensis gastric emptying
breath test meal. The normal range is also
shown.
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Responsiveness to treatment Several studies have
documented the effect of pharmacological agents on
the gastric emptying parameters in health and diseases
such as diabetes mellitus.37,41
Strengths and confounding issues No radiation is
involved and the test is simple and does not require any
special equipment on-site, and can be performed in the
office or bed side. There are pitfalls in the interpreta-
tion of this test. Theoretically, 13C-Spirulina platensis
requires digestion before absorption, and intestinal
mucosal disease, pancreatic or biliary insufficiency
may interfere with the test. 13C-octanoic acid breath
test performance should not be affected by these fac-
tors; as has been shown for cumulative 13CO2 excre-
tion in liver, kidney, lung disease.42,43
Recommendations 13C-GEBT is a simple, safe, radia-
tion-free and validated test for assessing gastric emp-
tying. It is used clinically in some centers in Europe,
but is not presently available for clinical use in USA.
Other techniques of measurement of gastric
emptying
Ultrasonography Transabdominal ultrasonography
measures emptying, and gastroduodenal flow.44
Serial changes of antral cross-sectional area can
provide an index of GE. Ultrasound determination is
operator dependent and has proven reliable only for
measurement of liquid emptying. Testing may be
difficult in obese individuals. Ultrasonography is
most commonly used in research settings. Duplex
sonography can quantify transpyloric flow of liquid
gastric contents and accommodation in the proximal
stomach whereas 3D ultrasonography can measure
gastric volume and emptying.45
Magnetic resonance imaging Magnetic resonance
imaging has been used to measure emptying, wall mo-
tion, and gastric volume, the latter being an index of
gastric accommodation. Transaxial abdominal scans are
generally obtained in the supine position every 15 min
before and after a predominantly liquid meal applying a
spin-echo technique with T1 weighted images.46 The
specialized equipment and expense, and the supine po-
sition have limited its role to research settings.
ASSESSMENT OF SMALL BOWEL TRANSIT
Altered transit of food and chyme through the small
bowel, particularly stasis due to an underlying myop-
athy (scleroderma) or neuropathy (diabetes) can cause
significant symptoms. Several tests are available for
the assessment of SBTT, and their pros and cons are
discussed in Table 2. They may be an alternative to
manometry, an invasive test with limited availability.
Transit measurement is a helpful tool for physiological
and pharmacodynamic studies of small bowel motor
function.
Overall indications
The main indication for assessment of SBTT is the
evaluation of subjects with unexplained nausea, vom-
iting, bloating, visible distention, or other manifesta-
tions of small intestinal bacterial overgrowth (SIBO) or
dysmotility.
Breath tests
Introduction Breath testing to quantify orocecal tran-
sit time (OCTT) involves ingesting a non-digestible
carbohydrate substrate like lactulose which upon
contact with enteric bacteria is metabolized to liberate
gases (hydrogen, methane, carbon dioxide etc.) which
diffuse across the mucosa, are transported to the lungs,
and expired in breath. Orocecal transit time reflects
gastric and small bowel transit.
Study performance End-expiratory breath samples are
acquired at baseline and at regular intervals after con-
suming 10 g of lactulose.47 Orocecal transit time is
defined as time interval between ingestion and when
sustained (5–10 parts per million) rises in hydrogen are
detected by gas chromatography (Fig. 4).
Data analysis, endpoints, and performance character-
istics Orocecal transit times range from 53 to 208 min








Validated ++ ++ +




Availability ++ + ++
Test performance & need
for specialized personnel
++ ++ ++
Patient inconvenience ++ ++ ++
Patient tolerance ++ +++ +++
Radiation exposure ) ++ ) or +**
Expense + ++ ++
*Depends on whether capsule retention is suspected.
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in health, with high intra-subject (14–39%) and inter-
subject (up to 56%) variabilities. Mean inter-individual
COV (21 healthy subjects) was 18.5%, 30%, and 28%
with doses of lactulose of 10, 15, and 20 g respec-
tively.48 Orocecal transit time with breath tests show
variable correlation with barium radiography or scin-
tigraphy. The correlation coefficients range from 0.31
to 0.95.49 The differences in transit times between
breath tests and scintigraphy are in part due to the time
required for substrate metabolism and hydrogen
transport to the lungs.
Other proposed methods include measuring breath
13CO2 after lactose-
13C-ureide;50 this has been tested
with different meal substrates.51 With duodenal infu-
sion of the substrate, it is possible to selectively
quantify SBTT.
Clinical significance Breath testing has been used to
quantify OCTT in health and disease: accelerated
transit in lactose intolerance and other diarrheal con-
ditions, and delayed transit in constipation, inflam-
matory/autoimmune disorders (Crohn’s disease, celiac
disease, scleroderma), hormonal conditions (pregnancy,
hypothyroidism), cystic fibrosis, and neurologic dis-
ease. Prokinetic drugs and serotonin reuptake inhibi-
tors accelerate OCTT, whereas opiates, contraceptives,
and tricyclic agents retard transit.
Strengths and confounding issues Strengths of breath
testing to assess OCTT include ease of performance,
low expense, and safety which permits use in popula-
tions (e.g., pregnancy) in whom scintigraphy would be
contraindicated. Limitations of breath testing that
confound its utility to measure OCTT include identi-
fication of the peak, potential acceleration of SBTT and
deceleration of GE with lactulose, an osmotic laxa-
tive,47,49 and significance of the peak as a measure of
transit in the setting of potential SIBO including short
bowel syndrome, or those with ileal pouches, prior
gastric retention, and irritable bowel syndrome.47
Early hydrogen peaks in SIBO can obscure hydrogen
production from colonic metabolism, making OCTT
determination impossible. Finally, exercise, smoking
and exhalation technique can affect results of
testing.47–49
Recommendations The orocecal transit time with
lactulose provides semi-quantitative assessment of
small bowel transit and may be useful in subjects for
whom more precise methods are not available, too
expensive, or too dangerous. Its shortcomings out-
weigh its benefits for assessment of small bowel transit
in clinical practice.
Scintigraphy
Introduction Assessment of SBTT using radionuclide
scintigraphy is usually performed as part of a whole gut
transit study.
Study performance The test involves ingestion of ei-
ther a liquid (water)2,52 or solid (resin beads or
meal),13,53,54 material labeled with 111In or 99mTc, and
obtaining sequential scans over several hours.
Data analysis and endpoints Small bowel transit time
can be calculated in several ways,55 but most com-
monly as the time for 10% or 50% of the activity to
arrive at the terminal ileum or cecum, after correcting
for GE.56 A valid surrogate for the 10% SBTT is the
percent of the meal filling the colon at 6 h.13 Thus, a
study can be deemed normal or abnormal, based on the
percentage of activity arriving at these regions within a
specified time, typically 6 h.
Performance characteristics Normative data are lim-
ited (n < 30 subjects), with wide ranges for SBTT that
are method-dependent.54,57,58 Consequently, the test is
only diagnostic if extreme values are obtained. Rapid
SBTT has been defined as >70% colonic filling at 6 h,13
or cecal arrival time of <90 min.2 Delayed SBTT has
variably been defined as colonic filling of <11% or
<40% at 6 h.2,13 Neither age nor gender appear to
influence SBTT,54,58 but there is significant inter-
(30%) and intra-subject (19%) variability for the
colonic filling at 6 h (CF6), a surrogate for SBTT.8 In a
study of 95 participants [healthy and irritable bowel
syndrome (IBS)], the mean CF6 was 51 ± 3% and the
estimated inter-subject COV was 56%.59 However,























Figure 4 Lactulose hydrogen breath test: This shows examples of a
subject with a normal lactulose hydrogen breath test and a subject
with accelerated (abnormal) orocecal transit time.
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CF6 is a measure of OCTT and could be significantly
influenced by GE rate.
Responsiveness to treatment Responsiveness of SBTT
to treatment was shown in studies of the effect of
cisapride in patients with gastroparesis and chronic
intestinal dysmotility60,61 and of tegaserod in patients
with IBS-constipation.62
Clinical significance Identification of delayed SBTT
has been shown to alter both initial diagnosis and
clinical management.63 However, a confounder is that
delayed colonic transit will delay SBTT and therefore
SBTT needs to be interpreted with caution in patients
with delayed colonic transit or constipation. Data on
clinical outcomes are limited.
Strengths and confounding issues Scintigraphy pro-
vides physiological and quantitative information.
However, the technique is not standardized, the nor-
mal range is wide, and interpretation potentially
compromised with abnormal gastric or colonic transit.
The gamma camera costs, radiation, need for prolonged
scanning time, and difficulty in delineating anatomy
are other drawbacks.
Recommendations Scintigraphy is recommended for
detection of altered small intestinal transit in subjects
with suspected diffuse GI motility disorder but is
available in a limited number of centers.
Wireless motility capsule
Introduction and indications Measurement of SBTT
has been performed with WMC.27,28,64,65 It is indicated
for detection of generalized dysmotility or as part of
evaluation of WGTT.
Study performance Measurement of SBTT is based
upon validated stereotypical changes in pH profile,
namely a rise in pH from acid to near neutral as the
capsule exits the stomach, and a fall of >1 pH unit from
the alkaline environment of the terminal ileum as it
passes into the large bowel.66,67 Time between the two
events is taken as SBTT (Fig. 2).
Data analysis, endpoints, and performance character-
istics Large normative data sets are available.27,28,68
Median SBTT has been reported as 4.6 h (4.0–5.9 h,
25th and 75th percentiles),28 although measurement is
influenced by timing of capsule ingestion in relation to
the test meal. Small bowel transit time in both gast-
roparetic and constipated subjects has been pub-
lished.27,28,64 The interindividual COV in SBTT for
health, gastroparesis and constipation were 33%, 33%,
and 37% respectively.
Clinical significance Small bowel transit time is pro-
longed in some patients with symptoms of upper and
lower GI dysmotility,69 but its clinical utility is as yet
unclear.
Strengths and confounding issues The WMC over-
comes the need for radiation and is a standardized
test. Furthermore, the subject is ambulant and
recordings can be carried out at home. Determi-
nation of SBTT is not possible in some subjects
(5–10%), as pH landmarks cannot be accurately
identified.27,64
Recommendations The WMC is a standardized, radi-
ation-free method for assessment of small bowel tran-
sit and is recommended for clinical use to facilitate
detection of small bowel dysfunction in subjects with a
more generalized GI motility disorder.
Other techniques for assessment of SBTT
Alternative methods include the use of video capsule
endoscopy70 or magnetic pill.71 For capsule endoscopy,
analysis of endoluminal visual data, using computer
vision techniques, allows for recognition of intestinal
contractile patterns. Small bowel transit time is deter-
mined by visual detection of capsule exit from the
stomach and arrival in the cecum.70
Capsules have the advantage of simplicity, minimal
discomfort and performance in ambulatory setting.
Their drawbacks include that capsules are likely to
empty from the stomach with resumption of fasting
pattern of motility thereby providing data on small
bowel transit during fasting and that their movement
may not reflect that of chyme, and their retention in
stomach or small bowel if lumen is obstructed may
limit its use.
ASSESSMENT OF COLONIC TRANSIT
Disorders of colonic motility typically present with
constipation or diarrhea, and often affect colonic
transit time (CTT). The availability of a simple, safe
and reliable method to quantify CTT is therefore of
significant diagnostic importance in the evaluation of
these patients, and may help to select appropriate
therapies. Two methods of assessing CTT, radio-
opaque markers and colonic scintigraphy, are well
established; a third procedure involving a WMC has
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been recently validated. The pros and cons of common
techniques are discussed in Table 3.
Radioopaque markers
IntroductionMeasurement of CTT using radioopaque
markers (ROM) was first described in 1969 and has
been widely adopted.72
Indications Radioopaque marker testing is indicated
to differentiate between normal and slow colonic
transit in patients with constipation, to assess seg-
mental transit times in patients with delayed total
colon transit, and to assist in the evaluation of unex-
plained diarrhea.
Study performance Radioopaque markers are plastic
beads or rings that are usually ingested in a capsule
(Sitzmarks; Konsyl Pharmaceuticals, Easton, MD,
USA) or with a meal. Abdominal X-rays are performed
at predetermined times and the number of retained
markers is counted (Fig. 5). Radioopaque markers test
measures WGTT. However, as most of the WGTT
reflects passage through the colon, the test is an
approximation of CTT.
Data analysis and endpoints Different protocols for
ROM measurement of CTT have been described which
affects analysis and interpretation.
1 A single capsule containing 24 markers followed
by a single abdominal X-ray on day 5 (120 h later).
Retention of ‡5 markers (Fig. 5) is abnormal.27 There is
limited radiation exposure; however no quantitative
information on CTT is provided.
2 Twenty-four markers of similar or different shapes
are ingested daily for 3–6 consecutive days and X-rays
are obtained on day 4 and 7 (or only on day 7).73–76
Transit time is quantitated because equilibrium
between daily marker output and input is achieved
by the time radiographs are taken.
3 A single dose of markers is ingested and serial
X-rays are obtained every 24 h until no markers are
visible. This method is time consuming, inconvenient
and produces greater radiation exposure.72
Performance characteristics Normative data for CTT
from a large number of ROM studies are available for
adults and children.74–77 In most studies, the mean
CTT is 30–40 h with an upper limit of normal of 70 h
in mixed populations. Women have longer maximal
CTT (70–106 h) compared to men (50 h).77 In one study
of regional colonic transit, total CTT was 35 ± 2 h
(mean ± standard error) with 11.3 ± 1.1 h for the right
colon, 11.4 ± 1.4 h for the left colon, and 12.4 ± 1.1 h
for the rectosigmoid.75 Thus, the inter-subject COV is
51.3%. In a second study, overall CTT in men was 31 h
and in women 36 h.76 Thus, the estimated inter-sub-
ject COV in men is 19.4% and in women 42%.76
Differences in CTT reported between studies may re-
flect differences in age and gender ratios and method-
ology among studies. Some studies have observed fair









Validated +++ +++ +++
Standardized + ++ +++
Provides accurate and
quantitative results
+ or ++* +++ +++
Availability +++ + ++
Test performance & need
for specialized personnel
++ +++ ++
Patient inconvenience + or ++* +++ ++
Patient tolerance +++ +++ +++
Radiation exposure + or ++ or +++* ++ ) or +
Expense + ++ ++
*Depends on technique of ROM test; If capsule retention is suspected.
Figure 5 Radioopaque marker colonic transit test: This X-ray was
taken at 120 h after ingestion of a single capsule containing 24 radio-
opaque markers in a subject with chronic constipation. It shows
retention of several ring-shaped plastic markers indicating delayed
colonic transit.
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degrees of reproducibility of CTT measurements on
repeated study with mean difference 0.4 ± 0.8 days
(mean ± SD), and 0.4 days respectively.73,76 Intra- and
inter-observer variabilities are low; the coefficient for
intra-observer repeatability and limits of agreement
between two observers were found to vary between 2
and 4 markers.78 This was further improved when a
colonic barium trace was added.78 Colonic transit time
measured by ROM and scintigraphy methods are sim-
ilar, even though the center of mass of the ROMs
propagates slightly ahead of the scintigraphic tracer.79
Likewise, correlations between CTT with ROM and
the WMC are good.27
Responsiveness to treatment The ROM technique has
been used in several pharmacotherapeutic studies to
asses the effects of drugs on altering colonic transit.
Acceleration of CTT with ROM was associated with
improvement in bowel symptoms in constipated
patients in several clinical trials that evaluated poly-
ethylene glycol,80 tegaserod,81 and prucalopride.82
Clinical significance Radioopaque markers measure-
ments of CTT are widely used in clinical practice and
research; they may distinguish constipation sub-
groups.73,74 However, 60% of patients with dyssyn-
ergic defecation have delayed CTT.83 Hence, anorectal
physiological tests are required to definitively identify
subjects with slow transit constipation alone. The
ROM test quantified CTT with reasonable accuracy
in patients with diarrhea secondary to bile acid
malabsorption.84
Strengths and confounding issues The ROM methods
are widely available, safe, repeatable, non-invasive,
and inexpensive. The main drawbacks of ROM
testing are lack of standardization between centers,
errors with interpretation of test results, inconve-
nience and lack of patient compliance (e.g., intake of
multiple capsule or attendance for X-rays), and radi-
ation exposure (Table 3). Future validation studies are
needed to standardize the number of ROMs ingested,
the timing of X-rays, the methods of reporting, and
to develop normative values and performance char-
acteristics with a consensus method. Such data are
not available and hence interpretation of results is
still suspect despite 4 decades of use in clinical
practice.
Recommendations The ROM study is recommended
for clinical evaluation of CTT in subjects with
constipation and irritable bowel syndrome. It is rela-
tively inexpensive and widely available.
Colonic transit scintigraphy
Introduction Colonic transit scintigraphy (CTS) is
performed following ingestion of a radioactive meal or
labeled non-absorbable charcoal to examine the transit
of meal residues through the colon. It has been used as
a biomarker in drug development for disorders of co-
lonic motor activity.85 The test offers reproducible and
accurate performance across a spectrum of disorders,
linking colonic transit measurements to symptoms
and disease processes, and demonstrating response to
treatment.
Indications Test is indicated to measure whole gut
and regional colonic transit in patients with suspected
colonic motility disorders or more diffuse disorders
involving the stomach or small intestine.2,85,86
Study performance Two methods have been described:
Temple University2,56 assesses colon transit of 111In
DTPA-labeled water consumed in a standard solid-
liquid meal for gastric scintigraphy and Mayo Clinic87,88
uses a capsule (containing 111In adsorbed on activated
charcoal) coated with the pH-sensitive polymer meth-
acrylate that dissolves in the alkaline terminal ileum,

















GC24 = 2.5 GC48 = 4.0
GC24 = 1.33 GC48 = 2.74
Figure 6 Colonic transit scintigraphy: This shows examples of
colonic transit scintigraphic images (A) from a healthy subject with a
normal geometric center (GC) count at 24 and 48 h and (B) from a
subject with constipation showing abnormally low values for
geometric center of a isotope meal at 24 and 48 h due to retention of
radioisotope in the colon indicating delayed colonic transit.
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Data analysis and endpoints Two end points are used
to summarize colonic transit: (i) a numeric value of
overall colonic transit, expressed as the geometric
center (based on seven regions at Temple, five regions
at Mayo), and (ii) ascending colon emptying summa-
rized as the T1/2 (time for 50% emptying). Concurrent
validity has been demonstrated relative to radioopaque
markers.79,88
Performance characteristics These have been ap-
praised in health and IBS. In 21 healthy volunteers who
underwent CTS twice, 3 weeks apart, interindividual
COV were 37% at 24 h and 24% at 48 h, while intra-
individual COVs were 28% and 14%, respectively.89 In a
study of healthy individuals and IBS-Constipation (IBS-
C) patients, COVintra was 31% at 24 h and 27% at 48 h
over a short-term period of <3 weeks and 38% at 24 h
and 30% at 48 h over a median interval of 2 years.59 The
COV reflects the known variation in stool frequency
and consistency in IBS-Diarrhea (IBS-D) patients. No
significant differences were observed in replicate stud-
ies in IBS-C and IBS-Mixed (IBS-M). One grade change in
Bristol stool consistency scale is associated with a 0.6–
0.7 change in colonic geometric center at 24 or 48 h.59
Responsiveness to treatment Pharmacodynamic CTS
studies have correctly predicted degrees of efficacy
(using symptom-based end points) in phase IIB or III
trials of medications with diverse mechanisms of
action, including alosetron, tegaserod, prucalopride,
linaclotide, and lubiprostone85 demonstrating thera-
peutic responsiveness.
Clinical significance Colonic transit scintigraphy
quantifies slow colonic transit in patients with con-
stipation and can influence patient management.2,90
Additionally, CTS can determine if the motor abnor-
mality is diffuse or localized to a specific colonic
region.2,88,90,91 Colonic transit scintigraphy identified
accelerated colonic transit in patients with IBS-D and
about 20% of patients with IBS-C.90
Measurement of WGTT also helps direct treatment.
If WGTT is delayed, prokinetic treatment may be
indicated. With severe slow transit constipation,
responses to colectomy are better in patients with
isolated colonic dysfunction than in those with associ-
ated gastric and/or small bowel transit delays.92 If
WGTT is normal, patient education, dietary advice, and
osmotic laxatives may be more useful than prokinetics
or surgery. The clinical utility of scintigraphic testing
was demonstrated in 104 patients including 73 patients
with constipation as initial clinical diagnoses.2 Colonic
transit scintigraphy changed the initial clinical diagno-
sis in 47/104 (45%) and altered patient management in
70/104 (67%) of the patients.
Strengths and confounding issues There is biologic
plausibility, stable performance characteristics, and
association with the clinical alteration of bowel func-
tion in diseases that affect colonic motility that all
support use of CTS as a marker to validate new treat-
ments and to help direct patient care.2,85
Recommendations Colonic transit scintigraphy is
recommended for assessing colonic transit in patients
with constipation or diarrhea but is available in a
limited number of centers.
Wireless motility capsule
Introduction The WMC is a new technique of assess-
ing colonic and whole gut transit.
Indications The WMC test is indicated in patients
with suspected bowel disorders including chronic
constipation and to distinguish slow from normal co-
lonic transit. Measurement of combined small and
large bowel transit time (SLBTT) is performed as a
surrogate measure of colonic transit in chronic con-
stipation when CTT alone cannot be determined.
Study performance The WMC transit protocol is dis-
cussed above under gastric emptying (Fig. 2A,B).
Data analysis and endpoints Cecal entry is defined as
a distinct, sustained (>10 min) pH drop of >1 unit that
occurs ‡30 min after gastric emptying. Colonic transit
time is defined as the time between cecal entry and
capsule exit from the body (loss of signal and/or an
abrupt temperature drop). Small and large bowel transit
time is defined as the time between gastric emptying
and body exit, and is calculated when cecal entry
cannot be detected (5% of cases).
Performance characteristics Large studies have con-
firmed its performance characteristics and utility in
quantifying CTT when compared to conventional
tests,26,27,64 (Table 3). There was good agreement
between the WMC and ROM transit results. The
inter-subject COV for CTT was 68, and 67% in health
and constipation respectively. Correlation coefficients
of CTT by WMC relative to ROM expelled on day 2
and day 5 were 0.74 and 0.69 in constipation, and 0.70
and 0.40 in healthy controls.27
In a prospective study, GET, CTT and WGTT
measured by WMC were slower in 78 constipated
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subjects (Rome II) VS 87 healthy controls (P < 0.01).27
The diagnostic accuracy and specificity of CTT (WMC)
to predict constipation from ROC were 0.73 and 0.95,
respectively; these were comparable to values of 0.71
and 0.95 for day 5 ROM. Thus, WMC correlated well
with ROM and discriminated normal from slow
colonic transit.
In 158 patients with chronic constipation who
underwent simultaneous CTT measurement using
ROM and WMC,64 the positive device agreement
between WMC and ROM for delayed transit was
80% and negative device agreement (normal transit)
was 91%. Correlation coefficients between ROM VS
WMC for CTT and SLBTT were 0.71 and 0.70,
respectively. There was 87% agreement validating
WMC relative to ROM in differentiating slow VS
normal CTT in constipation. Moreover WMC and
scintigraphic WGTT show good correlation.93 The
intra-class correlation coefficients for GET, SBTT,
CTT, and WGTT measurements in a combined group
of 45 healthy, gastroparetic and constipated subjects
were 1.0, 0.93, 0.99, and 1.0 respectively.94 There was
excellent inter-rater agreements for regional and
WGTT between three independent raters with varying
degrees of experience.94 Another study showed that
80% of healthy subjects remain within the normal or
abnormal range when test is repeated with a COV of
60%.95 In two studies, Bristol stool form but not stool
frequency showed modest correlations (R = 0.39) with
WMC measures of WGTT and CTT in mixed popula-
tions confirming the need for objective testing when
precise estimates of gut transit are necessary.64,96
Clinical significance The diagnostic utility of WMC
VS conventional motility tests was assessed in 86
patients stratified into upper GI (UGI, n = 36), and
lower GI (LGI, n = 50) dysfunction.69 In addition to
confirming a clinical suspicion and good device agree-
ment, significant new diagnostic information was
obtained with WMC in the UGI (P = 0.001) and LGI
(P = 0.006) groups when compared to conventional
motility tests. Moreover WMC detected a motility
disorder affecting more than one region in 51% of
subjects.69,97 It influenced management in 30% of LGI
and 88% of UGI subjects.69 In another study, WMC
lessened the need for further invasive motility tests.97
Strengths and confounding issues The WMC is well-
tolerated, exhibits good compliance, and measures
CTT and WGTT under ambulatory conditions with-
out radiation exposure. However, it requires physi-
cian training for interpretation, and device failure is
reported in 3% of cases. It has not yet been
tested for colonic responsiveness to pharmacological
agents.
Recommendations The WMC is a validated and stan-
dardized test. It is recommended for assessment of
colonic transit time in subjects with constipation and
those with suspected colonic disorders. It also provides
measurements of regional and whole gut transit.
CONCLUSIONS
A variety of tests are available to assess GI transit in the
clinical evaluation of patients with symptoms of
dysmotility. Measurements of gastric emptying time
using scintigraphy of a radiolabeled solid or liquid meal
or a WMC are useful in clinical practice for assessment
of gastric emptying. 13C-GEBT may also be useful but is
presently not available for clinical use in USA. Mea-
surements of small bowel transit time using WMC and
scintigraphy provide useful assessments of altered small
bowel function. Assessment of orocecal transit time
with lactulose breath test is simple but is less accurate.
Measurements of colonic transit time have been tradi-
tionally performed with radioopaque marker test.
Recently WMC and colonic scintigraphy have been
validated for detection of both abnormal colonic transit
and whole gut transit. All three modalities are clinically
useful for detection of altered colonic transit, although
scintigraphy is only available in limited centers.
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